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Ethnopharmacological relevance: Rhizoma Anemarrhenae has been used in Asian countries for thousands
of years to treat diabetes. Insulin resistance (IR) is the primary cause responsible for type 2 diabetes. The
aim of this study was to to assess the hypoglycemic and insulin sensitizing properties of Rhizoma An-
emarrhenae extract (TFA) in animal models of insulin resistance and/or diabetes and to delineate modes
of action.
Materials and methods: In-vivo studies were performed on STZ-induced diabetic mice and KK-Ay mice,
the former of which were given the extract alone or in combination with insulin for 7 days, and the latter
of which were given the extract for 8 consecutive weeks. Fasting blood glucose and serum insulin levels
were measured. Pancreatic tissue sections were examined using transmission electron micrographs.
Further, hyperinsulinemic–euglycemic clamping study was conducted in BCG vaccine-induced insulin
resistance rats, and glucose infusion rate was examined. Mechanisms of action were investigated in 3T3-
L1 and Hela cells using Western blot analysis.
Results: Our study showed that TFA enhanced the glucose-lowering effects of exogenous insulin ad-
ministration in STZ-induced diabetic mice. Therapeutic administration of TFA signiﬁcantly reduced
fasting blood glucose, and serum insulin levels, and markedly increased the size and the number of
insulin-producing beta cells in KK-Ay mice. Further, hyperinsulinemic–euglycemic clamping study
showed that glucose infusion rate was signiﬁcantly improved in TFA-treated BCG vaccine-induced insulin
resistance rats. Study of mechanism of action revealed that TFA increased phosphorylation of AMPK and
its downstream target, acetyl-CoA carboxylase (ACC) in 3T3-L1 cells. It activates AMPK in a LKB1-in-
dependent manner, providing a uniﬁed explanation for the beneﬁcial effects of TFA.
Conclusions: This study that TFA mediates activation of AMPK and improves overall glucose and lipid
metabolism in diabetic rodents, highlights the potential utility of TFA for the management of type
2 diabetes.
& 2015 The Authors. Published by Elsevier Ireland Ltd. This is an open access article under the CC BY-NC-
ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Natural principles and crude extracts of plants have been a rich
resource for the development of novel therapeutics used to treat a
variety of human diseases such as type 2 diabetes (T2D). Ane-
marrhena asphodeloides Bunge. (Asparagaceae) yields Anemar-
rhenae Rhizoma, which has been commonly used in Asianr Ireland Ltd. This is an open acces
(W. Chen).
is study.countries for thousands of years to treat various ailments, like
febrile diseases, fever, cough and diabetes (Wang et al., 2014).
Modern research found that the water extracts of Anemarrhenae
Rhizoma displayed signiﬁcant hypoglycemic bioactitvities in dia-
betic animal models (Guo et al., 2011; Hoa et al., 2004; Ichiki et al.,
1998; Muruganandan et al., 2002; Muruganandan et al., 2005;
Nakashima et al., 1993; Wang et al., 1995,, 2014; Yoshikawa et al.,
2001). The bioassay-guided fractionation of the extract resulted in
isolation of active components such as mangiferin and its gluco-
side (mangiferin-7-O-β-D-glucoside), pseudoprototimosaponin
AIII, Anemarans A, B, C, and D, etc. Among these compounds,
mangiferin exhibits not only antihyperglycemic, but alsos article under the CC BY-NC-ND license
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blood glucose, plasma total cholesterol, triglycerides, low density
lipoprotein-cholesterol (LDL-C) and increasing high density lipo-
protein (HDL-C) in diabetic animal models (Guo et al., 2011; Ichiki
et al., 1998; Muruganandan et al., 2002, 2005; Yoshikawa et al.,
2001), probably through activation of liver AMPK (Niu et al., 2012).
The hypoglycemic mechanism of pseudoprototimosaponin AIII
might be related to inhibition of hepatic gluconeogenesis and/or
glycogenolysis (Nakashima et al., 1993). In the Chinese Pharma-
copoeia 2010, Anemarrhena asphodeloides has been described to
have the effect on treating diabetes due to internal heat and
constipation (Committee, 2010). Up to now, 108 compounds have
been isolated from Anemarrhena asphodeloides, including steroidal
saponins, ﬂavonoids, phenylpropanoids, alkaloids, steroids, or-
ganic acids, anthraquinones, and others. However, to our knowl-
edge a role for Anemarrhena asphodeloides and its ingredients in
obesity-induced insulin resistance has not been previously
demonstrated.
The prevalence of type 2 diabetes (T2D) and comorbidities
continues to increase (Association, 2014). Insulin resistance (IR) is
the primary cause responsible for type 2 diabetes. So there is
considerable interest in the discovery of insulin sensitizing agents
to aid in the treatment of this disease. Metformin is such an insulin
sensitizer against IR by increasing peripheral glucose uptake while
reducing hepatic glucose production in an AMPK-dependent
manner (Viollet et al., 2012).
AMPK is a major cellular energy sensor and a master regulator
of metabolic homeostasis (Zhang et al., 2009). In mammalian tis-
sues, AMPK is a heterotrimeric protein kinase consisting of a cat-
alytic (α) and two regulatory subunits (β and γ) (Viollet et al.,
2006). AMPK is activated by two distinct signals: a
Ca2þ-dependent pathway mediated by CaMKKβ and an AMP-de-
pendent pathway mediated by LKB1 (Sanders et al., 2007). Current
study suggests a close link between dysregulation of AMPK and IR
in both rodents and humans. AMPK activity is diminished in adi-
pose tissue of very obese insulin-resistant people (Xu et al., 2012).
In model systems, sustained decreases in AMPK activity accom-
pany IR, whereas AMPK activation increases insulin sensitivity
(Steinberg and Kemp, 2009). On the other hand, AMPK can be
activated by exercises and calorie restriction, which have long
been known to increase insulin sensitivity and decrease the pre-
valence of T2D (Knowler et al., 2002). In addition, pharmacological
agents developed for the treatment of type 2 diabetes, such as
metformin, TZDs, GLP1 agonists, and dipeptidyl peptidase IV (DPP
IV) inhibitors, have all been shown to activate AMPK, and in sev-
eral instances, have demonstrated utility in preventing the pro-
gression of impaired glucose tolerance to type 2 diabetes (De-
Fronzo et al., 2011; Knowler et al., 2002; LeBrasseur et al., 2006;
Nawrocki et al., 2006; Svegliati‐Baroni et al., 2011; Viollet et al.,
2012). So AMPK becomes an attractive target for treatment of T2D.
TFA, the Rhizoma Anemarrhenae extract, was composed of two
main compounds, mangiferin and neomangiferin (details see
Section 2.3). To the best of our knowledge, there are still no reports
on the effect of TFA on diabetes. The objective of our study is to
assess the hypoglycemic and insulin sensitizing properties of TFA
in animal models of insulin resistance and/or diabetes and to de-
lineate modes of action.2. Material and methods
2.1. Chemicals and reagents
Compound C (CC), and STO-609 were purchased from Sigma-
Aldrich (St. Louis, MO, USA). Neomangiferin and mangiferin stan-
dards were from National Institute for the Controlof Pharmaceutical and Biological Products (NICPBP, Beijing, China).
Wortmannin was from Selleck Chemicals (Houston, TX, USA). Re-
ference substances for HPLC were of HPLC quality and purchased
from Merck (Darmstadt, Germany). Solvents used for extraction
were of analytical grade.
Rhizoma Anemarrhenae (radix of Anemarrhena asphadeloides
Bge.) was purchased from Shanghai LeiYunshang Pharmaceutical
Company (Shanghai, China). The crude drug was identiﬁed by
Professor Wan-sheng Chen, and a voucher specimen (accession
number ZM-2009-10) has been deposited in Changzheng Hospital,
Shanghai.
2.2. Cell lines
Murine 3T3-L1 preadipocytes and LKB1-deﬁcient Hela cells
were obtained from Shanghai Institute of Cell Biology, Chinese
Academy of Sciences (Shanghai, China).
2.3. Preparation of the TFA extract
Dried Rhizoma Anemarrhenae (10 kg) was extracted with 70%
aqueous ethanol (40 L) by percolation for 48 h. The collected ex-
tracts were ﬁltered and concentrated to yield liquid extract (about
8 L) by a rotatory evaporator in vacuo. The ethanol extract was
chromatographed over a ZTC-1 macroporous resin column eluted
with water and 20% ethanol later. The 20% ethanol extracts were
dried in vacuo and grinded into powder for use as Rhizoma Ane-
marrhenae extract (pale yellow powder, about 0.15 kg) (Chen, W.
S., 2003).
The primary stock solution of neomangiferin (1.96 mg) was
prepared in 70% ethanol in a 2 mL volumetric ﬂask to be
0.98 mg/mL. The primary stock solution of mangiferin
(0.98 mg/mL) was prepared in the same procedure. Then, the
mixed standard solutions of neomangiferin and mangiferin (both
98 μg/mL) were obtained by diluting the primary stock solutions
of neomangiferin and mangiferin by 70% ethanol. The primary
stock solution of TFA (2.20 mg) was prepared in 70% ethanol in a
2 mL volumetric ﬂask to be 1.10 mg/mL, from which obtained the
testing TFA solution at 110 μg/mL using 70% ethanol for dilution.
Fingerprint analysis and compound determination was per-
formed using an established HPLC-DAD method (ZHANG et al.,
2014). An Agilent 1200 liquid chromatography system was applied
for analysis, equipped with a quaternary solvent delivery system,
an autosampler and a photodiode array detector (DAD). A Dia-
monsil C18 column (4.6 mm250 mm, 5 μm, Dikma) was used for
analysis at 1.0 mL min1 and at 25 °C. The mobile phase consisted
of acetonitrile (eluent A) and water with 0.1% acetic acid (Tedia,
United States of America, eluent B), using a linear gradient elution:
2–20% A (0–30 min); 20–22% A (30–35 min); 22–26% A (35-
40 min); 26–35% A (40-60 min); 35–55% A (60–75 min); 55–95% A
(75–85 min). Representative HPLC chromatograms of TFA were
shown in Fig. 1. The contents of two main compounds in TFA,
neomangiferin and mangiferin, were 15.32% and 46.82%,
respectively.
2.4. Protein analysis
3T3-L1 preadipocytes or Hela cells were serum starved for
overnight, and then treated with TFA at 30 mg/mL for 2 h at 37 °C.
CC (40 mM) or STO-609 (10 mg/mL) was added 30 min before the
initiation of treatment. Western blot analysis was performed by
standard methods with antibodies directed against total AMPK,
phosphorylated AMPK, total ACC, and phosphorylated ACC that
were obtained from Cell Signaling Technology (Danvers, MA, USA).
The phospho-AMPK antibody detects endogenous AMPKα1 and
α2 when phosphorylated at Thr172.
Fig. 1. Representative HPLC-DAD ﬁngerprint chromatograms of TFA at 260 nm (A), 280 nm (B) and 230 nm (C). Peaks: 1, neomangiferin; 2, mangiferin.
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Mouse experiments were conducted in 6- to 8-week-old male
and female ICR, and KK-Ay mice (Institute of Laboratory Animal
Sciences, Chinese Academy of Medical Science, Beijing, China). Rat
experiments were conducted in male and female Sprague-Dawley
(SD) rats (180–210 g). Experimental animals unless noted were
purchased from Slac Laboratory Animal Co. Ltd. (Shanghai, China).
All animal procedures were performed in accordance with the
guidelines of the institutional animal care and use committee of
the Second Military Medical University. Animals were maintained
on a 12-h light/dark cycle and fed ad libitum unless noted. Animals
were acclimated for 7 days in the research facility before initiation
of the experiments. The STZ mice model was developed as follows.
Normal 6-week-old ICR mice were given a single intraperitoneal
injection of 200 mg/kg STZ (Sigma-Aldrich, St. Louis, MO, USA).One week after STZ injection, mice exhibiting 6-h fasting blood
glucose410 mM were considered to have type 2 diabetes. All the
diabetic animals were randomized to treatment groups based on
fasting blood glucose levels (n¼16–20). TFA were administered
once daily by oral gavage for 7 days at 30, 90, and 270 mg/kg,
respectively. 0.8% Carboxymethyl cellulose sodium in distilled
water was used as the vehicle. Pioglitazone (Pio, National Medicine
Group Shanghai Chemical Reagent Co., Ltd., Shanghai, China)
30 mg/kg/d was used as a positive control. 6-h fasting blood glu-
cose was monitored after 7 days. One week after drug withdrawal,
mice were given insulin protamine zinc (Shanghai No. 1 Biochem-
ical & Pharmaceutical Co., Ltd., Shanghai, China. 0.2 U/mouse/d, s.
c.) once a day for 4 consecutive weeks. The treatment was initiated
3 weeks after insulin injection. Mice with similar blood glucose
concentrations (n¼16–20) were treated with TFA or Pio for 7 days
using the treatment regimen mentioned above. For the studies
Table 1
Effects of TFA on fasting blood glucose levels in normal SD rats.
Group n Fasting blood glucose (mmol / L)
Day 0 Day 7
Vehicle 10 2.770.11 2.570.12
TFA 20 mg/kg 10 2.670.09 2.570.11
TFA 60 mg/kg 10 2.770.08 2.870.18
TFA 180 mg/kg 10 2.670.09 2.670.09
Pio 20 mg/kg 10 2.670.13 2.570.08
TFA: total ﬂavonoids from Anemarrhena Asphodeloides Bge. Pio: pioglitazone.
Results are expressed as mean7SEM.
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same treatment regimen previously described for 8 weeks. Six-
hour fasting plasma glucose was monitored weekly. Plasma insulin
levels were measured by radioimmunoassay (LINCO, St. Charles,
MO). A homeostasis model assessment of insulin resistance
(HOMA-IR), an index of insulin resistance, was calculated using
fasting insulin and glucose concentrations according to the fol-
lowing equation (Haffner et al., 1997; Matthews et al., 1985).
HOMA IR fasting insulin IU/mL fasting glucose nmol/L
/22.5
− = ( (μ ) × ( ))Fig. 2. Effects of TFA on fasting blood glucose levels in mice with STZ-induced
diabetes. (A) STZ-induced diabetic mice were treated orally with TFA (30, 90,
270 mg/kg) or Pio (30 mg/kg) for 7 days. (B) STZ-induced diabetic mice were
treated with insulin 0.2 IU mouse per day for 21 days, and then treated with the
same dose of insulin in combination with TFA or Pio for 7 consecutive days. Veh :
Vehicle. Results are expressed as mean7SEM. **Po0.01 vs. STZ/Veh group.At the end of the study, pancreas, livers, kidneys and hearts of
KK-Ay mice were ﬁxed in 10% buffered formaldehyde and em-
bedded in parafﬁn, cut in 5 mm sections, and stained by standard
hematoxylin/eosin procedures. Pancreatic tissue sections were
also prepared for transmission electron microscopic (TEM) ex-
amination as previously described (Carlson et al., 2003).
2.6. Hyperinsulinemic–euglycemic clamps
Experiments were conducted in SD rats. As previously de-
scribed (Guo et al., 2002), rats were administered a single i.v. in-
jection of 10 mg Bacillus Calmette-Guérin (BCG, Shanghai Institute
of Biological Products, Shanghai, China) per rat to establish an
animal model of immune insulin resistance, and control rats were
injected with the same volume of saline. All the BCG vaccine-in-
duced insulin resistance rats (BCG-rats) were randomized to
treatment groups based on fasting blood glucose levels (n¼10).
Then, TFA were administered once daily orally for 14 days at 20
(BCG/TFA 20), 60 (BCG/TFA 60), and 180 mg/kg (BCG/TFA 180),
respectively. 0.8% Carboxymethyl cellulose sodium in distilled
water was used as the vehicle (BCG/Vehicle). Pio 20 mg/kg/d was
used as a positive control (BCG/Pio 20). After a 14-day treatment
period and an overnight fast, clamps were performed on these
BCG-rats and WT SD rats (n¼10). Body weight was measured, and
then a blood sample was taken from the tail for the assessment of
the basal glucose concentration. After being anesthetized with
sodium pentobarbital (30 mg/kg i.p.), an indwelling catheter for
infusion of insulin and glucose was placed into the right jugular
vein. Rats were allowed to recover for 10 min, then a hyper-
insulinaemic–euglycaemic clamp study was conducted in these
rats. The insulin clamp was begun at t¼0 min with a primed-
continuous infusion of human insulin (16 mU/kg bolus followed by
8 mU kg1 min1). 5 min later, a continuous infusion of glucose
was given at a rate of 1 mg kg1 min1 for the remainder of the
experiment. Plasma glucose concentration was monitored every
10 min, and the infusion rate of exogenous glucose (GIR) was ad-
justed appropriately to maintain the baseline glucose level. Record
GIR at a time when a steady blood glucose level (3.8–4.0 mM,
lasted at least 30 min) was reached.2.7. Statistics
All data are expressed as mean7SE. Statistical analysis was
conducted by using Student's t test. Statistical signiﬁcance was
deﬁned as Po0.05.3. Results
3.1. Effects of TFA on glycemic control in normal SD rats
To evaluate the effects of TFA on glycemic control in normal
rats, TFA or Pio was administered orally once daily for 7 con-
secutive days. As shown in Table 1, TFA and Pio had no signiﬁcant
effects on fasting blood glucose in normal SD rats.
3.2. Effects of TFA on glycemic control in mice with STZ-induced
diabetes
To generate a nongenetic rodent model mimicking human type
2 diabetes, ICR mice were given a single injection of 200 mg/kg
STZ. As shown in Fig. 2, 1–2 weeks after STZ injection, the blood
glucose of untreated STZ-induced diabetic mice (STZ/Veh) rised to
14.7–16.0 mmol/L, 5–6 week after STZ treatment, the blood glu-
cose of STZ/Veh remained at 21.0–23.0 mmol/L, well above that of
vehicle-treated non-diabetic mice without STZ injection (Veh).
Furthermore, treatment with insulin (0.2 U/mouse/d, s.c.) in
combination with Pio (30 mg/kg/d, p.o.) for 7 days signiﬁcantly
reduced PP fasting blood glucose (83%) in these STZ-induced dia-
betic mice, validating the suitability of the STZ mouse model for
pharmaceutical testing. We therefore performed a 7-day study to
test the effect of TFA or Pio on glycemic control in the STZ mouse
model. As shown in Fig. 2A, treatment with TFA (30, 90, or 270 mg/
kg) or Pio (30 mg/kg) alone had little effect on fasting blood
Table 2
Effects of TFA on fasting blood glucose levels (mM) in KK-Ay mice.
Treatment weeks Group
Vehicle n¼13 TFA 30 n¼12 TFA 90 n¼12 TFA 270 n¼13 Pio 30 n¼13
0 12.370.9 12.671.1 12.370.9 12.471.3 12.471.3
1 12.871.2 11.671.5 12.171.3 11.471.0 10.171.1
2 15.470.9# 10.571.0** 11.671.3* 12.071.1* 8.670.6**,#
3 15.871.4 9.870.8** 10.070.7**,# 8.670.6**,# 8.470.5**,#
4 17.471.4## 9.770.8**,# 9.370.5**,## 11.071.0** 8.070.5**,##
5 17.971.6## 9.270.7**,# 9.070.6**,## 12.571.2**,# 7.670.7**,##
6 18.971.7## 8.470.7**,## 8.970.8**,## 9.770.7**,# 7.370.5**,##
7 19.471.4## 7.970.7**,## 8.770.6**,## 9.970.6**,# 6.470.3**,##
8 20.771.6## 7.770.6**,## 8.670.6**,## 8.570.6**,## 6.570.3**,##
Results are expressed as mean7SEM.
n Po0.05.
nn Po0.01 vs. the vehicle-treated group.
# Po0.05.
## Po0.01 vs. corresponding group before treatment.
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21 days caused mild reduction in fasting blood glucose (5.6–9.8%,
P40.05). However, treatment with insulin (0.2 U/mouse/d, s.c.) in
combination with TFA or Pio for 7 days thoroughly attenuated the
increase of fasting blood glucose levels (n¼16–20, Po0.01 vs. STZ/
Veh, Fig. 2B), suggesting that TFA and insulin acted synergistically
to improve glucose metabolism in this nongenetic mouse model of
type 2 diabetes.
3.3. Effects of TFA on metabolic control in KK-ay mice
To fully characterize the effects of TFA on metabolic control, we
performed an 8-week study in diabetic KK-Ay mice. As illustrated
in Table 2 and Figs. 3, 6-h fasting blood glucose levels of the ve-
hicle-treated group increased gradually and reached a peak valueFig. 3. Effects of TFA on fasting blood glucose levels (A), fasting plasma insulin levels (B)
as mean7SEM. *Po0.05, ***Po0.001 vs. the vehicle-treated group.of 20.7 mM by the end of treatment, while that of TFA-treated
groups decreased gradually to 7.7–8.5 mM, signiﬁcantly lower
than that of the vehicle group and of corresponding groups before
treatment.
The effects of TFA on plasma insulin levels were also de-
termined. TFA signiﬁcantly reduced plasma insulin levels (Fig. 3B).
Thus, TFA effectively reduced hyperglycemia and hyperinsulinemia
in this KK-Ay mouse model of type 2 diabetes.
The HOMA-IR index provides a simple method to measure in-
sulin sensitivity, and its use is widespread in both clinical and
animal studies (1). In our study, the HOMA-IR index was sig-
niﬁcantly decreased in the TFA groups ( Fig. 3C). Collectively, these
results demonstrated TFA improved glycemic control and insulin
sensitivity in KK-Ay mice., and the insulin resistance index HOMA-IR (C) in KK-Ay mice. Results are expressed
Fig. 4. Representative hematoxylin and eosin (H&E) staining (1000 ) and trans-
mission electron micrographs (7500 ) of pancreatic tissue sections from KK-Ay
mice with TFA or Pio treatment for 8 weeks.
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We next characterized the inﬂuence of different treatment re-
gimens on the morphological appearance of pancreas, liver, kid-
ney, and heart tissue compartments.
Fig. 4 shows typical H&E staining and transmission electron
micrographs of pancreatic tissue sections from KK-Ay mice. H&E
staining showed that treatment with TFA or Pio results in a relative
normal pancreatic structure, a more clear outline of insulin-pro-
ducing beta cells which were markedly increased in numbers and
size. Using transmission electron microscope, we observed thatFig. 5. Representative hematoxylin and eosin (H&E) staining (400 ) of liver, kidney abeta cells in the KK-Ay pancreas showing nuclear shrinkage,
chromatin condensation and margination, and granular basophilic
cytoplasm, characteristic features of apoptosis. After 8-week
treatment with increasing doses of TFA or Pio, the characteristic
features of apoptosis were signiﬁcantly alleviated.
Fatty liver disease is commonly observed in type 2 diabetes and
obesity, and we therefore investigated the morphology of hepa-
tocytes by light microscopy. Hepatocytes of diabetic KK-Ay mice
displayed marked morphological changes with coalescing cyto-
plasmic vacuoles, which is strongly suggestive for accumulation of
fat droplets (Fig. 5). The increase of vacuoles was alleviated by TFA
as well as Pio. Further, treatment with TFA or Pio resulted in a
relative normal hepatic architecture with evenly-distributed cells
and arranged closely connective tissue, shortage of nuclear
shrinkage, clear nuclear outline, characteristics of attenuation of
hepatic cellular apoptosis. Thus, these data suggest that both
agents decreased lipid accumulation associated with diabetes in
non-adipose tissues such as liver.
The H&E staining of kidney tissue sections from KK-Ay mice
(Fig. 5) showed signiﬁcant vacuolar degeneration of renal tubular
cells with displaced pycnotic nuclei, mesangial hyperplasia, and
tubulointerstitial nephropathy. After 8-week treatment with TFA
or Pio, the above pathological changes were apparently lessened,
cellular apoptosis was alleviated, and inﬂammatory cell inﬁltration
was also signiﬁcantly attenuated.
As Fig. 5 shown, no abnormal coronary vascular and myocardial
structural changes were observed before and after treatment with
TFA or Pio.3.5. Effects of TFA on insulin sensitivity
We induced insulin resistance in SD rats by a single i.v. injec-
tion of 10 mg BCG (Guo et al., 2002). Hyperinsulinemic–eu-
glycemic clamp analysis also revealed these rats to be insulin re-
sistant: the glucose infusion rate (GIR) was reduced by 41% in the
BCG vaccine-induced insulin resistance rats (BCG-rats) compared
with the vehicle controls (Table 3). Furthermore, GIR was sig-
niﬁcantly improved in Pio-treated BCG-rats (Table 3), demon-
strating the validity of the BCG vaccine-induced insulin resistance
rat model for pharmaceutical testing. As shown in Table 3, GIR rose
with increasing doses of TFA, suggesting that TFA enhance insulin
action and improve insulin-stimulated glucose disappearance in
these BCG-rats.nd heart tissue sections from KK-Ay mice with TFA or Pio treatment for 8 weeks.
Table 3
Effects of TFA on glucose infusion rates (GIR) during a hyperinsulinemic–euglycemic clamp experiment in BCG vaccine-induced insulin resistance rats.
Group Vehicle BCG/vehicle BCG/TFA 20 BCG/TFA 60 BCG/TFA 180 BCG/Pio 20
Glucose (mM) 3.870.15 4.070.14 3.870.12 3.870.13 3.870.17 3.970.14
GIR (mg/kg min) 14.1770.27** 8.3970.31 13.3570.28** 14.3370.32** 14.7670.23** 14.8970.35**
BCG vaccine-induced insulin resistance rats were fasted for 6 h before the experiment. The insulin clamp was begun at t¼0 min with a primed-continuous infusion of human
insulin 16 mU/kg bolus followed by 8 mU kg1 min1. Blood was acquired from the cut tail in restrained mice. Data are mean7SEM for 10 mice/group.
nn Po0.01 vs. the vehicle-treated group.
Fig. 6. TFA promote phosphorylation of AMPK and ACC in vitro. 3T3-L1 preadipocytes (A) or Hela cells (B) were treated with TFA in the presence or absence of compound C
or STO-609 for 2 h. Then cells were lysed, and phospho-speciﬁc antibodies were used to determine phosphorylation of AMPK and ACC in immunoblots. After immunoblots
were stripped, anti-AMPK and anti-ACC antibodies were used to conﬁrm that protein loads were equal. Densitometric analyses and quantiﬁcation of the ratios pAMPK/AMPK
and pACC/ACC from experiments. **Po0.01 vs. basal levels. #Po0.05, ##Po0.01 vs. cells treated with the indicated compound in the absence of Compound C or STO-609.
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To investigate the mechanism of action for the antidiabetic
activity of TFA, we analyzed phosphorylation of AMPK by western
blotting. We found that TFA treatment resulted in a signiﬁcant
elevation of the phosphorylation at Thr-172 on the AMPKα2 sub-
unit in 3T3-L1 preadipocytes. TFA also increased the phosphor-
ylation of the AMPK target ACC (Fig. 6). Using an AMPK inhibitor
compound C, the ability of TFA to stimulate the phosphorylation ofAMPK and ACC was diminished (Fig. 6), suggesting that TFA pri-
marily activate AMPK by increasing its phosphorylation at Thr-172.
AMPK is primarily activated by two kinases, LKB1 and CaMKKβ.
We found TFA also stimulated AMPK and ACC phosphorylation in
the LKB1-deﬁcient HeLa cells (Fig. 6). In addition, CaMKKβ in-
hibitor STO-609, at a nontoxic concentration (Pang et al., 2008;
Turner et al., 2008), reduced the effect of TFA on AMPK and ACC
phosphorylation in 3T3-L1 preadipocytes and Hela cells (Fig. 6).
These results indicated that TFA activated AMPK and ACC in a
J. Han et al. / Journal of Ethnopharmacology 172 (2015) 368–376 375LKB1-independent fashion. Further, CaMKKβ may play a role in
AMPK activation stimulated by TFA.4. Discussion
The present study has revealed that TFA is an insulin sensitizer.
TFA was shown to be an effective antihyperglycaemic agent on
genetically diabetic KK-Ay mice (Fig. 3, Table 2). The blood glu-
cose-lowering action of TFA was marked and sustained (Fig. 3,
Table 2). It was associated with a substantial reduction of hyper-
insulinaemia and an apparent increase in pancreatic insulin stores
(Figs. 3 and 4). The HOMA-IR index provides a simple method to
measure insulin sensitivity, and its use is widespread in both
clinical and animal studies. In our study, the HOMA-IR index sig-
niﬁcantly decreased in the TFA groups (Fig. 3). Furthermore, an
independent indicator of insulin sensitivity, the glucose infusion
rate was improved during hyperinsulinaemic–euglycaemic clamp
studies in TFA-treated BCG vaccine-induced insulin resistance rats
(Table 3). So it is not surprising that TFA and insulin act sy-
nergistically to reduce blood glucose of STZ-induced diabetic mice
(Fig. 2B). TFA alone had little effect on the STZ-induced diabetic
mice because the inability of their pancreas to synthesize insulin
precluded any potential effects mediated by altered insulin re-
sistance (Szkudelski, 2001) (Fig. 2A).
The reason we did not observe a dose response between 30 and
270 mg/kg of TFA may be that the dose range studied was too high.
Most clinical mangiferin studies in the literature administered 10–
30 mg/kg (Miura et al., 2001; Muruganandan et al., 2002, 2005),
which is equal to 21–64 mg/kg of TFA (The content of mangiferin
in TFA is 46.82%). Therefore, a dose-response effect of TFA may
plateau beyond 30 mg/kg. On the other hand, though there were
no signiﬁcant differences among the doses, 30, 90, and 270 mg/kg
of TFA all decreased hyperglycemia and hyperinsulinemia sig-
niﬁcantly compared with 0 mg/kg (vehicle). That is, doses within
the range of 30–270 mg/kg appeared to be equally effective.
AMPK acts as a fuel sensor, sensing the body insulin sensitivity
against IR. We found that TFA stimulated AMPKa and ACC phos-
phorylation not only in 3T3-L1 cells, but also in Hela cells which
do not express LKB1 (Fig. 6). Furthermore, AMPK activation in Hela
and 3T3-L1 cells was inhibited by treatment with the CaMKKß
inhibitor STO-609, indicating that TFA-induced activation of AMPK
was partly mediated by the CaMKK signaling pathway, but not by
LKB1signaling (Fig. 6). Consistent report that mangiferin activated
AMPK in liver of hyperlipidemic rats (Niu et al., 2012).
Activation of AMPK may play an important role in the hy-
poglycemia effects of TFA. AMPKα2 KO animals exhibited in-
creased body weight and fat mass on a high-fat diet (Villena et al.,
2004). In contrast, acute hepatic overexpression of a constitutively
active AMPKα2 subunit results in reduced blood glucose and in-
creased hepatic fatty acid oxidation (Foretz et al., 2005). Firstly,
AMPK activation decreases hepatic glucose output. As an AMPK
activator, metformin has been used for decades to improve gly-
cemic control in diabetic patients and is thought to decrease blood
glucose levels by reducing hepatic glucose output through in-
hibition of transcription of key gluconeogenic genes in the liver
(Shaw et al., 2005). Secondly, AMPK activation enhances cellular
glucose transport in muscle and adipose tissue via activation of
GLUT1 and GLUT4 (Barnes et al., 2002; Zheng et al., 2001). AICAR,
a well-known AMPK activator, enhanced glucose uptake in skeletal
muscle, and this effect was abolished in skeletal muscle from
AMPK inactive mutant mice (Mu et al., 2001). Thirdly, activation of
AMPK increases phosphorylation of ACC, a key enzyme in the
regulation of fatty acid metabolism. The phosphorylation and in-
activation of ACC results in decreased levels of malonyl CoA, which
in turn activates carnitine palmitoyltransferase 1 (CPT1) toincrease fatty acid oxidation and reduces de novo fatty acid
synthesis (Ruderman et al., 2003). Hepatocytes of diabetic KK-Ay
mice displayed marked morphological changes with coalescing
cytoplasmic vacuoles, which are strongly suggestive for accumu-
lation of fat droplets (Fig. 5). The increase of vacuoles in KK-Ay
mice was alleviated by TFA as well as Pio (Fig. 4). Our ﬁnding that
TFA reduced hepatocellular lipids indicates that the activation of
AMPK may account for its lipid-lowering actions. Metformin-in-
duced reduction in hepatic lipid content is consistent with an in-
crease in fatty acid oxidation presumably acting through hepatic
AMPK activation (Zang et al., 2004). On the other hand, It is in-
dicated that hepatic steatosis contributes to insulin resistance
(Ryysy et al., 2000). Increased hepatic fatty acid ﬂux has been
postulated to play a role in this process (Day and Saksena, 2002).
Both TFA and Pio reduce hepatic vacuoles accumulation in KK-Ay
mice, thereby probably contributing to improved insulin sensitiv-
ity in both treatment groups.
Taken together, our results indicate that TFA mediates activa-
tion of AMPK and improves overall glucose and lipid metabolism.5. Conclusions
In conclusion, the present study has demonstrated that
8 weeks of TFA treatment in KK-Ay mice signiﬁcantly alleviates
hyperglycemia and hyperinsulinaemia, and markedly increased
pancreatic insulin stores. So the HOMA-IR index markedly de-
creased in the TFA groups. Furthermore, an independent indicator
of insulin sensitivity, the glucose infusion rate was improved
during hyperinsulinaemic–euglycaemic clamp studies in TFA-
treated BCG vaccine-induced insulin resistance rats, illustrating
that TFA is an insulin sensitizer by enhancing insulin signaling. A
strong proof of this notion is TFA and insulin act synergistically to
reduce blood glucose of STZ-induced diabetic mice (Fig. 2B). Study
of mechanism of action revealed that TFA increased phosphor-
ylation of AMPK and its downstream target ACC. This study sug-
gests that TFA improves insulin sensitivity by activating AMPK, in a
mechanism which is independent of LKB1, providing a uniﬁed
explanation for the beneﬁcial effects of TFA. This highlights the
potential utility of TFA for the management of type 2 diabetes.Acknowledgments
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AMPK: AMP-activated protein kinase;;
ACC: acetyl-CoA carboxylase;;
BCG: Bacillus Calmette–Guérin;;
CC: compound C;;
CPT1: carnitine palmitoyltransferase 1;;
DPP IV: dipeptidyl peptidase IV;;
DAD: photodiode array detector;;
GIR: glucose infusion rate;;
HDL-C: high density lipoprotein;;
HOMA-IR: homeostasis model assessment of insulin resistance;;
IR: Insulin resistance;;
LDL-C: low density lipoprotein-cholesterol;;
STZ: streptozotocin;;
SD: Sprague-Dawley;;
S.C: Subcutaneous injection;;
TFA: Rhizoma Anemarrhenae extract;;
TEM: transmission electron microscopic;
T2D: type 2 diabetes;;
Veh: Vehicle..
